sunitinib ratiopharm 25 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 25 mg - sunitinibi
sunitinib ratiopharm 37.5 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 37.5 mg - sunitinibi
sunitinib ratiopharm 50 mg kapseli, kova
ratiopharm gmbh - sunitinib - kapseli, kova - 50 mg - sunitinibi
everolimus stada 2.5 mg tabletti
stada arzneimittel ag stada arzneimittel ag - everolimuusi - tabletti - 2.5 mg - everolimuusi
everolimus stada 5 mg tabletti
stada arzneimittel ag stada arzneimittel ag - everolimuusi - tabletti - 5 mg - everolimuusi
everolimus stada 10 mg tabletti
stada arzneimittel ag stada arzneimittel ag - everolimuusi - tabletti - 10 mg - everolimuusi
braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - antineoplastiset aineet - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.
everolimus avansor 2.5 mg tabletti
avansor pharma oy - everolimuusi - tabletti - 2.5 mg - everolimuusi
everolimus avansor 5 mg tabletti
avansor pharma oy - everolimuusi - tabletti - 5 mg - everolimuusi
everolimus avansor 10 mg tabletti
avansor pharma oy - everolimuusi - tabletti - 10 mg - everolimuusi